Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Nanoco's share price nearly doubles in a week

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Shares in cadmium-free quantum dot technology developer Nanoco (NANO) are on the move as the company signs a commercial supply agreement with a large US electronics manufacturer.
The news excited investors to chase the stock from 23.55p to heights of 44.35p, before easing back to the current 39.4p. But Shares believes that investors need to tread carefully. This may be the company's first actual supply deal for its cadmium-free quantum dot technology but Nanoco has had major licensing agreements to use the technology in place since 2014 (with Dow Chemical), with a second major agreement with Merck coming in 2016.
Yet meaningful revenue remains stubbornly elusive. Revenue in the year to 31 July 2017 barely topped £1.3m and was dwarfed by operating losses of £10.9m.
While the latest contract is welcome news, Nanoco has been seemingly on the cusp of a major financial breakthrough for years. Estimates for 2017 published by the company’s broker Peel Hunt in November 2016 suggested £7.8m of 2017 sales, rising to £21.9m in 2018.
Those estimates proved wildly optimistic with 2018 revenues now anticipated at £7.5m, demonstrating how long it takes for commercialisation to find scale.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.